Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer

G. Melloni, P Muriana, Alessandro Bandiera, R Fontana, D Maggioni, V Russo, C Doglioni, P Zannini

Research output: Contribution to journalArticle

Abstract

Introduction: In the search of new therapeutical strategies against non-small-cell lung cancer (NSCLC), the identification of new prognostic factors is crucial. Objectives: In this study, we analyzed the prognostic value of the liver X receptor-alpha (LXR-alpha), a nuclear receptor of a family of cholesterol derivatives called oxysterols, in patients with radically resected NSCLC. Methods: We retrospectively reviewed 140 stage II and III surgically treated NSCLC patients that were grouped by percentage of LXR-alpha-positive cells value above or below its median value. Tumor-related survival was evaluated as primary end point. Results: The 5-year overall and tumor-related survival rates were 40% and 46%, respectively. The median percentage of LXR-alpha-positive cells was 20%. Patients with stage II NSCLC had higher LXR-alpha values than those with stage III (P=.04). Univariate analysis demonstrated that both TNM stage and LXR-alpha were significantly related to tumor-related survival (P=.006 and P=.004, respectively). The 5-year tumor-related survival rates in stage II and III NSCLC were 56% and 34%, respectively. The 5-year tumor-related survival rates in high and low LXR-alpha value were 57% and 32%, respectively. The multivariate analysis showed that both TNM stage and LXR-alpha were independent prognostic factors (P=.01 and P=.007, respectively) with hazard ratio of 1.92 and 0.49, respectively. Conclusion: LXR-alpha seems to be an independent prognostic factor indicating a better survival in completely resected stage II and III NSCLC patients. © 2016 John Wiley & Sons Ltd.
Original languageEnglish
Pages (from-to)241-246
Number of pages6
JournalClinical Respiratory Journal
Volume12
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Survival Rate
Neoplasms
Survival
Liver X Receptors
Cytoplasmic and Nuclear Receptors
Nuclear Family
Multivariate Analysis
Cholesterol

Cite this

Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer. / Melloni, G.; Muriana, P; Bandiera, Alessandro; Fontana, R; Maggioni, D; Russo, V; Doglioni, C; Zannini, P.

In: Clinical Respiratory Journal, Vol. 12, No. 1, 2018, p. 241-246.

Research output: Contribution to journalArticle

Melloni, G. ; Muriana, P ; Bandiera, Alessandro ; Fontana, R ; Maggioni, D ; Russo, V ; Doglioni, C ; Zannini, P. / Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer. In: Clinical Respiratory Journal. 2018 ; Vol. 12, No. 1. pp. 241-246.
@article{76f26b567c47453e9de6e72e3e210f47,
title = "Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer",
abstract = "Introduction: In the search of new therapeutical strategies against non-small-cell lung cancer (NSCLC), the identification of new prognostic factors is crucial. Objectives: In this study, we analyzed the prognostic value of the liver X receptor-alpha (LXR-alpha), a nuclear receptor of a family of cholesterol derivatives called oxysterols, in patients with radically resected NSCLC. Methods: We retrospectively reviewed 140 stage II and III surgically treated NSCLC patients that were grouped by percentage of LXR-alpha-positive cells value above or below its median value. Tumor-related survival was evaluated as primary end point. Results: The 5-year overall and tumor-related survival rates were 40{\%} and 46{\%}, respectively. The median percentage of LXR-alpha-positive cells was 20{\%}. Patients with stage II NSCLC had higher LXR-alpha values than those with stage III (P=.04). Univariate analysis demonstrated that both TNM stage and LXR-alpha were significantly related to tumor-related survival (P=.006 and P=.004, respectively). The 5-year tumor-related survival rates in stage II and III NSCLC were 56{\%} and 34{\%}, respectively. The 5-year tumor-related survival rates in high and low LXR-alpha value were 57{\%} and 32{\%}, respectively. The multivariate analysis showed that both TNM stage and LXR-alpha were independent prognostic factors (P=.01 and P=.007, respectively) with hazard ratio of 1.92 and 0.49, respectively. Conclusion: LXR-alpha seems to be an independent prognostic factor indicating a better survival in completely resected stage II and III NSCLC patients. {\circledC} 2016 John Wiley & Sons Ltd.",
author = "G. Melloni and P Muriana and Alessandro Bandiera and R Fontana and D Maggioni and V Russo and C Doglioni and P Zannini",
year = "2018",
doi = "10.1111/crj.12522",
language = "English",
volume = "12",
pages = "241--246",
journal = "Clinical Respiratory Journal",
issn = "1752-6981",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer

AU - Melloni, G.

AU - Muriana, P

AU - Bandiera, Alessandro

AU - Fontana, R

AU - Maggioni, D

AU - Russo, V

AU - Doglioni, C

AU - Zannini, P

PY - 2018

Y1 - 2018

N2 - Introduction: In the search of new therapeutical strategies against non-small-cell lung cancer (NSCLC), the identification of new prognostic factors is crucial. Objectives: In this study, we analyzed the prognostic value of the liver X receptor-alpha (LXR-alpha), a nuclear receptor of a family of cholesterol derivatives called oxysterols, in patients with radically resected NSCLC. Methods: We retrospectively reviewed 140 stage II and III surgically treated NSCLC patients that were grouped by percentage of LXR-alpha-positive cells value above or below its median value. Tumor-related survival was evaluated as primary end point. Results: The 5-year overall and tumor-related survival rates were 40% and 46%, respectively. The median percentage of LXR-alpha-positive cells was 20%. Patients with stage II NSCLC had higher LXR-alpha values than those with stage III (P=.04). Univariate analysis demonstrated that both TNM stage and LXR-alpha were significantly related to tumor-related survival (P=.006 and P=.004, respectively). The 5-year tumor-related survival rates in stage II and III NSCLC were 56% and 34%, respectively. The 5-year tumor-related survival rates in high and low LXR-alpha value were 57% and 32%, respectively. The multivariate analysis showed that both TNM stage and LXR-alpha were independent prognostic factors (P=.01 and P=.007, respectively) with hazard ratio of 1.92 and 0.49, respectively. Conclusion: LXR-alpha seems to be an independent prognostic factor indicating a better survival in completely resected stage II and III NSCLC patients. © 2016 John Wiley & Sons Ltd.

AB - Introduction: In the search of new therapeutical strategies against non-small-cell lung cancer (NSCLC), the identification of new prognostic factors is crucial. Objectives: In this study, we analyzed the prognostic value of the liver X receptor-alpha (LXR-alpha), a nuclear receptor of a family of cholesterol derivatives called oxysterols, in patients with radically resected NSCLC. Methods: We retrospectively reviewed 140 stage II and III surgically treated NSCLC patients that were grouped by percentage of LXR-alpha-positive cells value above or below its median value. Tumor-related survival was evaluated as primary end point. Results: The 5-year overall and tumor-related survival rates were 40% and 46%, respectively. The median percentage of LXR-alpha-positive cells was 20%. Patients with stage II NSCLC had higher LXR-alpha values than those with stage III (P=.04). Univariate analysis demonstrated that both TNM stage and LXR-alpha were significantly related to tumor-related survival (P=.006 and P=.004, respectively). The 5-year tumor-related survival rates in stage II and III NSCLC were 56% and 34%, respectively. The 5-year tumor-related survival rates in high and low LXR-alpha value were 57% and 32%, respectively. The multivariate analysis showed that both TNM stage and LXR-alpha were independent prognostic factors (P=.01 and P=.007, respectively) with hazard ratio of 1.92 and 0.49, respectively. Conclusion: LXR-alpha seems to be an independent prognostic factor indicating a better survival in completely resected stage II and III NSCLC patients. © 2016 John Wiley & Sons Ltd.

U2 - 10.1111/crj.12522

DO - 10.1111/crj.12522

M3 - Article

VL - 12

SP - 241

EP - 246

JO - Clinical Respiratory Journal

JF - Clinical Respiratory Journal

SN - 1752-6981

IS - 1

ER -